Abstract
In comparison to many other pharmaceutical dosage forms, the regulatory picture for quality aspects of pulmonary products is still undergoing rapid and dynamic evolution. The purpose of this chapter is to examine aspects of product testing, specifications, and their accompanying regulatory processes which on one hand might also be considered as yet further barriers by those seeking to bring new inhalation treatments into fruition while oppositely embraced by others as a way to preserve knowledge and prevent a repetition of harmful errors. These are discussed in reference to the divergent international views on how to manage the integration of drug product and device requirements.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
US National Institutes of Health National Heart, Lung and Blood Institute (2009) Morbidity and mortality: 2009 chart book on cardiovascular, lung, and blood diseases. http://www.nhlbi.nih.gov/resources/docs/2009_ChartBook.pdf. Accessed 3 May 2010
Cyr TD, Graham SJ, Li KY, Lovering EG (1991) Low first-spray drug content in albuterol metered-dose inhalers. Pharm Res 8:658
FDA. Guidance for industry: integration of dose-counting mechanisms into MDI drug products. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071731.pdf. Accessed 3 May 2010
Amidon GL, Lennernäs H, Shah VP, Crison JR (1995) A theoretical basis for a biopharmaceutics drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res 12(3):413–20
FDA. Draft guidance for industry: bioavailability and bioequivalence studies for nasal aerosols and nasal sprays for local action. http://www.fda.gov/downloads/Drugs/Guidance-ComplianceRegulatoryInformation/Guidances/ucm070111.pdf. Accessed 3 May 2010
European Medicines Agency (EMEA). Guideline on the requirements for clinical documentation for orally inhaled products (OIP) including the requirements for demonstration of therapeutic equivalence between two inhaled products for use in the treatment of asthma and chronic obstructive pulmonary disease (COPD) in adults and for use in the treatment of asthma in children and adolescents, available as http://www.ema.europa.eu/pdfs/human/ewp/415100enfin.pdf. Accessed 3 May 2010
Lee SL, Adams WP, Li BV, Conner DP, Chowdhury BA, Yu LX (2009) In vitro considerations to support bioequivalence of locally acting drugs in dry powder inhalers for lung diseases. AAPS J 11(3):414–23
Adams WP, Ahrens RC, Chen ML, Christopher D, Chowdhury BA, Conner DP, Dalby R, Fitzgerald K, Hendeles L, Hickey AJ, Hochhaus G, Laube BL, Lucas P, Lee SL, Lyapustina S, Li B, O’Connor D, Parikh N, Parkins DA, Peri P, Pitcairn GR, Riebe M, Roy P, Shah T, Singh GJ, Sharp SS, Suman JD, Weda M, Woodcock J, Yu L (2010) Demonstrating bioequivalence of locally acting orally inhaled drug products (OIPs): workshop summary report. J Aerosol Med Pulm Drug Deliv 23(1):1–29. http://www.pqri.org/pdfs/DTC/Articles/JAMP_article_final_draft.pdf. Accessed 3 May 2010
Denyer J, Nikander K (2006) Does the approval of VENTAVIS® with the I-neb™ AAD® system present a new approach to the regulatory approval of nebulized drugs with novel delivery devices? Poster published at RDD 2006, Boca Raton, FL
Intercenter agreement between The Center for Drug Evaluation and Research and The Center for Devices and Radiological Health, October 31, 1991. http://www.fda.gov/CombinationProducts/JurisdictionalInformation/ucm121177.htm. Accessed 3 May 2010
European Commission. Guidelines relating to the Application of the Council Directive 90/385/EEC on active implantable medical devices and Council Directive 93/42/EEC on medical devices. http://ec.europa.eu/enterprise/sectors/medical-devices/files/meddev/2_1_3____07-2001_en.pdf. Accessed 3 May 2010
Horhota S, Leiner S, Berger R, Purrington A, Kärger S, Lyapustina S, Butterworth N, Patel R, Davidson B, Johansson E, Grant A, Smith MA. Rationalized approach to chemistry, manufacturing and control (CMC) requirements for orally inhaled and nasal drug products (OINDPs) based on risk management. http://ipacrs.com/PDFs/Posters/Risk%20Management.pdf. Accessed 3 May 2010
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2011 Controlled Release Society
About this chapter
Cite this chapter
Horhota, S.T., Leiner, S. (2011). Developing Performance Specifications for Pulmonary Products. In: Smyth, H., Hickey, A. (eds) Controlled Pulmonary Drug Delivery. Advances in Delivery Science and Technology. Springer, New York, NY. https://doi.org/10.1007/978-1-4419-9745-6_22
Download citation
DOI: https://doi.org/10.1007/978-1-4419-9745-6_22
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4419-9744-9
Online ISBN: 978-1-4419-9745-6
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)
